A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505735-13-01

Acronym

IMG-007-201

Enrollment

Registered

2024-03-19

Start date

Unknown

Completion date

2024-04-26

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Brief summary

Incidence of TEAEs

Detailed description

PK parameters as data permit, Percentage change in EASI from Baseline to Week 12

Interventions

DRUG-

DRUGIMG-007 placebo is identical in formulation to that of the drug product minus the active ingredient.

DRUGIMG-007

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAEs	—

Secondary

Measure	Time frame
PK parameters as data permit, Percentage change in EASI from Baseline to Week 12	—

Countries

Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026